Tags

Type your tag names separated by a space and hit enter

Updated treatment for influenza A and B.
Am Fam Physician. 2000 Dec 01; 62(11):2467-76.AF

Abstract

Influenza causes significant morbidity and mortality and is responsible for considerable medical expenditures. Vaccination is the most effective public health measure to combat this illness. Amantadine and rimantadine are older antiviral agents that have been important adjuncts in the prevention and treatment of influenza A outbreaks. Zanamivir and oseltamivir are newer agents indicated for the treatment of both influenza A and B. For antiviral agents to be effective, they must be used within 48 hours of the onset of influenza symptoms. Antiviral agents reduce the duration of fever and illness by one to two and one-half days and also reduce the severity of some symptoms. Use of amantadine or rimantadine is appropriate if influenza virus A is known to be the predominant agent in a particular year or location. Data need to be evaluated on the development of resistance and use of the newer antiviral agents in geriatric patients, high-risk patients and children. For optimal use of antiviral agents, patients with influenza symptoms must present early, and family physicians must accurately and rapidly diagnose the illness.

Authors+Show Affiliations

Department of Family Medicine, Robert C. Byrd Health Sciences Center of West Virginia University, Charleston Division, 25301, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

11130232

Citation

Montalto, N J., et al. "Updated Treatment for Influenza a and B." American Family Physician, vol. 62, no. 11, 2000, pp. 2467-76.
Montalto NJ, Gum KD, Ashley JV. Updated treatment for influenza A and B. Am Fam Physician. 2000;62(11):2467-76.
Montalto, N. J., Gum, K. D., & Ashley, J. V. (2000). Updated treatment for influenza A and B. American Family Physician, 62(11), 2467-76.
Montalto NJ, Gum KD, Ashley JV. Updated Treatment for Influenza a and B. Am Fam Physician. 2000 Dec 1;62(11):2467-76. PubMed PMID: 11130232.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Updated treatment for influenza A and B. AU - Montalto,N J, AU - Gum,K D, AU - Ashley,J V, PY - 2000/1/11/pubmed PY - 2001/2/28/medline PY - 2000/1/11/entrez SP - 2467 EP - 76 JF - American family physician JO - Am Fam Physician VL - 62 IS - 11 N2 - Influenza causes significant morbidity and mortality and is responsible for considerable medical expenditures. Vaccination is the most effective public health measure to combat this illness. Amantadine and rimantadine are older antiviral agents that have been important adjuncts in the prevention and treatment of influenza A outbreaks. Zanamivir and oseltamivir are newer agents indicated for the treatment of both influenza A and B. For antiviral agents to be effective, they must be used within 48 hours of the onset of influenza symptoms. Antiviral agents reduce the duration of fever and illness by one to two and one-half days and also reduce the severity of some symptoms. Use of amantadine or rimantadine is appropriate if influenza virus A is known to be the predominant agent in a particular year or location. Data need to be evaluated on the development of resistance and use of the newer antiviral agents in geriatric patients, high-risk patients and children. For optimal use of antiviral agents, patients with influenza symptoms must present early, and family physicians must accurately and rapidly diagnose the illness. SN - 0002-838X UR - https://www.unboundmedicine.com/medline/citation/11130232/Updated_treatment_for_influenza_A_and_B_ L2 - http://www.aafp.org/link_out?pmid=11130232 DB - PRIME DP - Unbound Medicine ER -